|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-2-3
|
|
pubmed:abstractText |
Evidence supports the routine use of low-dose aspirin (ASA) in the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM). In 1997, the American Diabetes Association (ADA) recommended ASA prophylaxis for all diabetic patients over the age of 30 with one additional risk factor for cardiovascular disease (CVD). Our objective was to determine the adherence to the ADA guidelines for ASA therapy in DM using a national database.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0742-3225
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
112-7
|
|
pubmed:dateRevised |
2006-1-26
|
|
pubmed:meshHeading |
pubmed-meshheading:15690251-Adult,
pubmed-meshheading:15690251-Aged,
pubmed-meshheading:15690251-Aspirin,
pubmed-meshheading:15690251-Cardiovascular Diseases,
pubmed-meshheading:15690251-Diabetic Angiopathies,
pubmed-meshheading:15690251-Female,
pubmed-meshheading:15690251-Fibrinolytic Agents,
pubmed-meshheading:15690251-Guideline Adherence,
pubmed-meshheading:15690251-Humans,
pubmed-meshheading:15690251-Logistic Models,
pubmed-meshheading:15690251-Male,
pubmed-meshheading:15690251-Middle Aged,
pubmed-meshheading:15690251-Patient Compliance,
pubmed-meshheading:15690251-Platelet Aggregation Inhibitors,
pubmed-meshheading:15690251-Retrospective Studies,
pubmed-meshheading:15690251-Risk Factors,
pubmed-meshheading:15690251-Societies, Medical
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Aspirin for primary prevention in patients with diabetes mellitus.
|
|
pubmed:affiliation |
Kansas City University of Medicine and Biosciences, USA.
|
|
pubmed:publicationType |
Journal Article
|
